Clinical trials for geroprotective interventions require redesigned endpoints that prioritize outcomes relevant to aging populations while maintaining regulatory rigor. A hierarchical approach to trial design addresses the gap between traditional drug approval standards and the complexity of measuring meaningful health gains in older adults.
Key Points
- Hierarchical endpoint frameworks align geroprotective trials with clinical priorities
- Win statistics improve regulatory pathways for longevity interventions
- Current trial design inadequately captures aging-relevant health outcomes
Longevity Analysis
The aging research field has long struggled with a structural problem: standard clinical trial endpoints measure disease absence rather than functional capacity, vitality, or systems resilience in later life. This work addresses a critical bottleneck in translating geroscience discoveries into accessible interventions. When trials are designed to capture what actually matters—maintenance of physical capacity, cognitive reserve, independence, and quality of remaining lifespan—rather than narrowly defined disease markers, the research pipeline accelerates and interventions with genuine longevity potential reach clinical practice rather than remaining confined to animal models.
Original published by Nature Aging, by Mahmoud Abdellatif.